Analgesia Management in Bariatric Surgery

• Status: Completed
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Following laparoscopic bariatric surgery, multimodal analgesia is recommended to avoid the adverse effects of opioids by reducing their use. Although lidocaine, ketamine, and dexmedetomidine have been used as adjuvant analgesics, no studies have evaluated the superiority of their intra- and postoperative infusions as components of multimodal analgesia in bariatric surgery. The present study is aimed to compare lidocaine, dexmedetomidine, and ketamine in multimodal analgesia management following Sleeve Gastrectomy Surgery. Postoperative pain scores, the requirement for additional postoperative analgesia, retching, nausea and vomiting, time to mobilization, and hospital length of stay will be evaluated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ondokuz Mayıs University
• Treatments: Dexmedetomidine; Ketamine; Lidocaine

Criteria

Inclusion Criteria:

• Body mass index>35 kg/m2

• The American Society of Anaesthesiologists (ASA) physical status class II III

• Patients who will undergo an elective laparoscopic sleeve gastrectomy (LSG)

Exclusion Criteria:

• refusal to participate

• allergy to the study drugs

• chronic kidney disease (creatinine>150 μmol/L)

• mental illness

• liver, respiratory or oncological disease,

• cardiac dysfunction (ejection fraction <40%),

• uncontrolled hypertension,

• preoperative analgesic use,

• chronic pain,

• history of alcohol or drug addiction